Pfizer Inc. (NYSE:PFE) Stock Position Raised by Hanson & Doremus Investment Management

Hanson & Doremus Investment Management boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 138,165 shares of the biopharmaceutical company’s stock after purchasing an additional 6,265 shares during the period. Pfizer accounts for 0.6% of Hanson & Doremus Investment Management’s investment portfolio, making the stock its 27th biggest holding. Hanson & Doremus Investment Management’s holdings in Pfizer were worth $3,866,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Pfizer during the fourth quarter valued at $16,166,000. LGT Group Foundation lifted its position in shares of Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after purchasing an additional 18,274 shares in the last quarter. First Heartland Consultants Inc. boosted its holdings in shares of Pfizer by 43.3% during the fourth quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 3,933 shares during the period. ORG Partners LLC grew its position in Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Finally, Kempner Capital Management Inc. acquired a new position in Pfizer in the 1st quarter valued at approximately $2,439,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, September 9th. Finally, UBS Group lifted their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

Shares of NYSE:PFE opened at $29.27 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a 50 day moving average price of $29.21 and a 200 day moving average price of $28.12. The company has a market cap of $165.86 billion, a price-to-earnings ratio of -487.75, a PEG ratio of 1.04 and a beta of 0.68. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.42.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the company posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were paid a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.74%. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.